Elizabeth Tan Chiu

Summary

Country: USA

Publications

  1. ncbi request reprint Effects of tamoxifen on benign breast disease in women at high risk for breast cancer
    Elizabeth Tan-Chiu
    Cancer Research Network, 350 84th Avenue, Suite 305, Plantation, FL 33324, USA
    J Natl Cancer Inst 95:302-7. 2003
  2. ncbi request reprint Moving forward: Herceptin in the adjuvant setting
    Elizabeth Tan-Chiu
    Cancer Research Network Inc, 350 NW 84th Avenue, Suite 305, Plantation, FL 33324, USA
    Oncology 63:57-63. 2002
  3. ncbi request reprint Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience
    Sandra Franco
    Cancer Research Network, Florida, USA
    Breast Cancer Res Treat 88:103-8. 2004
  4. ncbi request reprint Lower-category benign breast disease and the risk of invasive breast cancer
    Jiping Wang
    Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 96:616-20. 2004
  5. ncbi request reprint Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience
    Soonmyung Paik
    National Surgical Adjuvant Breast and Bowel Project NSABP Operation Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 94:852-4. 2002
  6. ncbi request reprint Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
    Adam Brufsky
    Magee Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15123, USA
    J Clin Oncol 25:829-36. 2007
  7. ncbi request reprint Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials
    Irene L Wapnir
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 24:2028-37. 2006
  8. ncbi request reprint Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Elizabeth Tan-Chiu
    National Surgical Adjuvant Breast and Bowel Project NSABP, University of Pittsburgh, PA, USA
    J Clin Oncol 23:7811-9. 2005
  9. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
  10. ncbi request reprint Trastuzumab plus chemotherapy: convincing survival benefit or not?
    Charles L Vogel
    J Clin Oncol 23:4247-50. 2005

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Effects of tamoxifen on benign breast disease in women at high risk for breast cancer
    Elizabeth Tan-Chiu
    Cancer Research Network, 350 84th Avenue, Suite 305, Plantation, FL 33324, USA
    J Natl Cancer Inst 95:302-7. 2003
    ..We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women...
  2. ncbi request reprint Moving forward: Herceptin in the adjuvant setting
    Elizabeth Tan-Chiu
    Cancer Research Network Inc, 350 NW 84th Avenue, Suite 305, Plantation, FL 33324, USA
    Oncology 63:57-63. 2002
    ..The breadth of the ongoing Herceptin adjuvant trials will potentially allow the optimal treatment approach to be identified...
  3. ncbi request reprint Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience
    Sandra Franco
    Cancer Research Network, Florida, USA
    Breast Cancer Res Treat 88:103-8. 2004
    ..The use of fulvestrant earlier in the sequence of endocrine treatments may achieve better responses than observed in this heavily pretreated patient population...
  4. ncbi request reprint Lower-category benign breast disease and the risk of invasive breast cancer
    Jiping Wang
    Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 96:616-20. 2004
    ..This report evaluates the risk of breast cancer associated with this lower-category BBD (LC-BBD)...
  5. ncbi request reprint Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience
    Soonmyung Paik
    National Surgical Adjuvant Breast and Bowel Project NSABP Operation Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 94:852-4. 2002
    ..This report provides a snapshot of the quality of HER2 assays performed in laboratories nationwide...
  6. ncbi request reprint Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
    Adam Brufsky
    Magee Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15123, USA
    J Clin Oncol 25:829-36. 2007
    ..The addition of zoledronic acid to adjuvant letrozole therapy may protect against bone loss...
  7. ncbi request reprint Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials
    Irene L Wapnir
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 24:2028-37. 2006
    ..Locoregional failure after breast-conserving surgery is associated with increased risk of distant disease and death. The magnitude of this risk in patients receiving chemotherapy has not been adequately characterized...
  8. ncbi request reprint Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Elizabeth Tan-Chiu
    National Surgical Adjuvant Breast and Bowel Project NSABP, University of Pittsburgh, PA, USA
    J Clin Oncol 23:7811-9. 2005
    ..Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines...
  9. ncbi request reprint Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  10. ncbi request reprint Trastuzumab plus chemotherapy: convincing survival benefit or not?
    Charles L Vogel
    J Clin Oncol 23:4247-50. 2005
  11. ncbi request reprint Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
    Michael S Ewer
    J Clin Oncol 25:5532-3; author reply 5533-4. 2007